Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling
Abstract
This research develops a computational framework to quickly propose drugs with potential clinical impact for CRPC patients that are resistant to hormonal therapies. Furthermore, we identified a drug—COL-3—which showed high efficacy in clinical CRPC tumors displaying resistance to enzalutamide or abiraterone. We validated COL-3's preferential efficacy through a pair of isogenic CRPC cell line models and further demonstrated the utility of our pipeline for efficient discovery of drugs with clinical impact.
- Publication:
-
Proceedings of the National Academy of Science
- Pub Date:
- April 2023
- DOI:
- 10.1073/pnas.2218522120
- Bibcode:
- 2023PNAS..12018522Z